Literature DB >> 24145711

Metabolomics: integration of a new "omics" with clinical pharmacology.

L P James1.   

Abstract

The term "pharmacometabolomics" was coined in 2006 to reflect the potential of the predrug metabolomic signature to predict the postdrug response. Metabolomics can be used to examine the contribution of nongenomic factors, such as the environment, diet, or the gut microbiome, to the overall drug response. As such, the complexity of human biology afforded by metabolomics can complement genomic approaches, ultimately moving the discipline of clinical pharmacology closer to full implementation of personalized medicine.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24145711     DOI: 10.1038/clpt.2013.166

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  13 in total

1.  PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses.

Authors:  Liudmila L Mazaleuskaya; Katrin Sangkuhl; Caroline F Thorn; Garret A FitzGerald; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2015-08       Impact factor: 2.089

2.  Distribution of Exogenous and Endogenous CYP3A Markers and Related Factors in Healthy Males and Females.

Authors:  Jieon Lee; Andrew HyoungJin Kim; SoJeong Yi; SeungHwan Lee; Seo Hyun Yoon; Kyung-Sang Yu; In-Jin Jang; Joo-Youn Cho
Journal:  AAPS J       Date:  2017-05-18       Impact factor: 4.009

Review 3.  Pharmacomicrobiomics: the impact of human microbiome variations on systems pharmacology and personalized therapeutics.

Authors:  Marwa ElRakaiby; Bas E Dutilh; Mariam R Rizkallah; Annemarie Boleij; Jason N Cole; Ramy K Aziz
Journal:  OMICS       Date:  2014-05-02

4.  Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients.

Authors:  Jeannine S McCune; Donald E Mager; Meagan J Bemer; Brenda M Sandmaier; Barry E Storer; Shelly Heimfeld
Journal:  Cancer Chemother Pharmacol       Date:  2015-05-17       Impact factor: 3.333

5.  A Gateway between Omics Data and Systems Biology.

Authors:  Fabian V Filipp
Journal:  J Metabolomics Syst Biol       Date:  2013-11-01

6.  Urinary 6β-Hydroxycortisol/Cortisol Ratio Most Highly Correlates With Midazolam Clearance Under Hepatic CYP3A Inhibition and Induction in Females: A Pharmacometabolomics Approach.

Authors:  Kwang-Hee Shin; Li Young Ahn; Man Ho Choi; Ju-Yeon Moon; Jieon Lee; In-Jin Jang; Kyung-Sang Yu; Joo-Youn Cho
Journal:  AAPS J       Date:  2016-06-17       Impact factor: 4.009

7.  Systems toxicology: from basic research to risk assessment.

Authors:  Shana J Sturla; Alan R Boobis; Rex E FitzGerald; Julia Hoeng; Robert J Kavlock; Kristin Schirmer; Maurice Whelan; Martin F Wilks; Manuel C Peitsch
Journal:  Chem Res Toxicol       Date:  2014-01-21       Impact factor: 3.739

8.  Use of semantic workflows to enhance transparency and reproducibility in clinical omics.

Authors:  Christina L Zheng; Varun Ratnakar; Yolanda Gil; Shannon K McWeeney
Journal:  Genome Med       Date:  2015-07-25       Impact factor: 11.117

9.  Elevated baseline serum glutamate as a pharmacometabolomic biomarker for acamprosate treatment outcome in alcohol-dependent subjects.

Authors:  H W Nam; V M Karpyak; D J Hinton; J R Geske; A M C Ho; M L Prieto; J M Biernacka; M A Frye; R M Weinshilboum; D-S Choi
Journal:  Transl Psychiatry       Date:  2015-08-18       Impact factor: 6.222

Review 10.  Clinical Metabolomics: The New Metabolic Window for Inborn Errors of Metabolism Investigations in the Post-Genomic Era.

Authors:  Abdellah Tebani; Lenaig Abily-Donval; Carlos Afonso; Stéphane Marret; Soumeya Bekri
Journal:  Int J Mol Sci       Date:  2016-07-20       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.